



Use of MedDRA® in CTCAE and in the Biopharmaceutical Industry

Ann Setser, BSN, MEd
MedDRA MSSO

MedDRA® is a registered trademark of the International Federation of
Pharmaceutical Manufacturers and Associations (IFPMA)



MedDRA was developed under the auspices of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Board, which is composed of the six ICH parties, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and The World Health Organization, and is chaired by the IFPMA.



Objectives

- Demonstrate the relationship of CTCAE to MedDRA
- Illustrate use of MedDRA for CTCAE 'Other, specify' terms
- Application of MedDRA in data retrieval, presentation, and analysis
 - Standardised MedDRA Queries (SMQs)
- MSSO free training



3



MedDRA Definition

MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.

4





Regulatory Status of Mandate

- US FDA
 - Used in several FDA databases (AERS, VAERS, and CAERS)
 - Proposed Rule for Safety Reporting Requirements (2003): MedDRA for postmarketing safety reports
- Japanese Ministry of Health, Labour and Welfare
- Canada
 - Guidance Document for Industry - Reporting Adverse Reactions to Marketed Health Products
 - Guidance for Industry - Product Monograph (labeling)

7



Regulatory Status of Mandate

- European Union EudraVigilance database
 - New PV legislation (Directive and Regulation) effective July 2012 broadens AR definition:
 - Occurring in context of medication errors
 - With uses outside terms of marketing authorization
 - Misuse and abuse
 - In context of occupational exposures

8



Regulatory Status of Mandate (cont)

- European Union (cont)
 - Interface between EudraVigilance and EU Risk Management Plan
 - Summary of Product Characteristics guideline
 - MedDRA to be used throughout; in particular for Contraindications, Special warnings and precautions for use, and Undesirable effects sections
- ICH M4E Guideline on Common Technical Document
 - Recommended in adverse event summary tables

9



CTCAE v4.0

- Utilizes a small subset of MedDRA terms that are common in oncology practice
- Terms are recognized by the ICH community as practice standards
- Lists MedDRA LLTs organized by SOCs
- 'Other, specify' allows submission of verbatim


10



CTCAE v4.0

General disorders and administration site conditions					
Adverse Event	Grade				
	1	2	3	4	5
Fatigue	Fatigue relieved by rest	Fatigue not relieved by rest, limiting instrumental ADL	Fatigue not relieved by rest, limiting self care ADL	-	-
Definition: A disorder characterized by a state of generalized weakness with a pronounced inability to summon sufficient energy to accomplish daily activities.					
Fever	38.0 - 39.0 degrees C (100.4 - 102.2 degrees F)	>39.0 - 40.0 degrees C (102.3 - 104.0 degrees F)	>40.0 degrees C (>104.0 degrees F) for <=24 hrs	>40.0 degrees C (>104.0 degrees F) for >24 hrs	Death
Definition: A disorder characterized by elevation of the body's temperature above the upper limit of normal.					

11





12

MedDRA Browser - SOC View: MedDRA 15.0 - English
FileViewToolsAbout
<Select MedDRA Data>
Action
MedDRA 15.0 - English


SOC General disorders and administration site conditions
Body temperature conditions
Febrile disorders
Pyrexia

Pyrexia
Chills & fever
Chills and fever
Chronic fever
Cotton fever
Drug fever
Febricula
Febrile reaction
Fever
Fever chills
Fever of unknown origin
Fluctuating fever
Heat production increased
Heat retention
High temperature
Intermittent fever
Intermittent pyrexia
Periodic fever
PUO
Pyrexia
Pyrexia abnormal
Pyrexia drug
Pyrexia NOS
Pyrexia of unknown origin
Pyrexia of unknown origin (excl puerperal)
Pyrexial
Reaction febrile
Slight fever
Slight temperature
Spiking temperature

13

CTCAE v4.0

General disorders and administration site conditions					
Adverse Event	Grade				
	1	2	3	4	5
General disorders and administration site conditions - Other, specify 	Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated	Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL	Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of existing hospitalization indicated; disabling; limiting self care ADL	Life-threatening consequences; urgent intervention indicated	Death

14



CTCAE v3.0 Analysis Prior to MedDRA Harmonization

- CTCAE v3.0
 - Routine reporting (Phase 1, 2) ~ 383,000
 - Expedited reporting (All Phases) ~ 66,000
 - 'Other, specify' ~ 6,000
- 'Other, specify' Verbatim & MedDRA
 - Match 41%
 - Algorithmic match 23%
 - No match 36%

Setser, A. 2009 CTCAE Boot Camp Presentations

15

Example of MedDRA & CTCAE 'Other, specify'

Begin > 2. Enter AEs > 3. Course and Agent > 4. Reporter > 5. Select Report > 6. Describe Event > 7. Patient Details > 8. Pre-existing Conditions > 9. Prior Therapies > 10. Concoms > 11. Other Causes > 12. Device > 13. Labs > 14. Attribution > 15. Attachments > 16. Submit

Create expedited report: Enter basic AE information

Participant Ira Johnson (127832)
Study Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously T Advanced Colorectal Cancer (E3200)

Enter AEs

Instructions: Enter all AEs that should appear on this expedited report. For each AE, complete all the required fields, and then click Continue.
Note: The data you enter on this page will be used to confirm whether expedited reporting is required (based on the set of rules set up for this study). The results will be displayed on the next two pages

Primary adverse event

CTC version
CTC category
CTC term Neurology - Other (Specify, __) - 10029298
Type a portion of the CTC term you are looking for. If you select a category, only terms in that category will be shown.

Other (MedDRA) leucoenceph
10058905 - Acute haemorrhagic leucoencephalopathy
10058906 - Acute hemorrhagic leucoencephalopathy
10058993 - Acute hemorrhagic leucoencephalitis
10058994 - Acute haemorrhagic leucoencephalitis
10063761 - Reversible posterior leucoencephalopathy syndrome
10065551 - Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy

Grade
1: Mild
2: Moderate
3: Severe
4: Life-threatening; disabling
5: Death

Select from the list the most appropriate term describing the relationship of the event to the study interactions or interventions.

Hospitalization None
Expected No

Specify whether the AE is expected or not. "Unexpected" events are those that differ in nature, severity or frequency from what is described in the investigator's brochure or informed consent document. For agents under a CTEP IND, refer also to the AdEERS Agent Specific Adverse Event List (ASAE). For commercial agents or agents under a non-CTEP IND, refer also to the package insert.

16

Example of MedDRA & CTCAE 'Other, specify'

Enter AEs || Select Subject and Study || Enter Adverse Events - Mozilla Firefox

new History Bookmarks Tools Help

semanticsbits.com https://demo.semanticsbits.com/caaers/pages/ae/captureRoutine

Getting Started Latest Headlines

|| Enter AEs || Select Subje...

Subject (A2020-AD-00001) Armando Deschanel
Study (7848) A Phase II Trial of Intravenous Administration of Reovirus Serotype 3 - Dearing Strain
Course Cycle # 1; Start Date: 10/01/09

Adverse Events

Instructions Begin to enter the AE term below, select the appropriate term, and click "Add." Alternatively, click "Add Multiple" to browse and add several AE terms at once.

or

Fatigue (asthenia, lethargy, malaise), Grade: 3

Verbatim

*** Grade**

- ☐ 1: Mild fatigue over baseline
- ☐ 2: Moderate or causing difficulty performing some ADL
- ☒ 3: Severe fatigue interfering with ADL
- ☐ 4: Disabling

17



MedDRA Data Retrieval and Presentation: Points to Consider



MedDRA Data Retrieval and Presentation: Points to Consider

- An ICH-Endorsed Guide for MedDRA users on Data Output
- Developed by an ICH Expert Working Group
- Provides data retrieval and presentation options for industry or regulatory purposes
- Objective is to promote understanding of implications that various options for data retrieval have on accuracy and consistency of final output
- Current version available on MedDRA MSSO Web site (http://www.meddramssso.com/subscriber_library_ptc.asp)

19



Data Retrieval PTC Points Addressed

- General Principles
 - Quality of Source Data
 - Documentation of Data Retrieval and Presentation Practices
 - Do Not Alter MedDRA
 - Organization-Specific Data Characteristics
 - Characteristics of MedDRA that Impact Data Retrieval and Analysis
 - MedDRA Versioning
- General Queries and Retrieval
- Standardised MedDRA Queries
- Customized Searches

20



Standardised MedDRA Queries (SMQs)



Definition of SMQ

- Result of cooperative effort between CIOMS and ICH (MSSO)
- Groupings of terms from one or more MedDRA System Organ Classes (SOCs) related to defined medical condition or area of interest
- Included terms may relate to signs, symptoms, diagnoses, syndromes, physical findings, laboratory and other physiologic test data, etc., related to medical condition or area of interest
- Intended to aid in case identification



SMQ Benefits and Limitations

- Benefits
 - Application across multiple therapeutic areas
 - Validated reusable search logic
 - Standardized communication of safety information
 - Consistent data retrieval
 - Maintenance by MSSO/JMO
- Limitations
 - Do not cover all medical topics or safety issues
 - Will evolve and undergo further refinement even though they have been tested during development

23



SMQs in Production - Examples

- As of Version 15.0, a total of 86 in production
 - Agranulocytosis
 - Anaphylactic reaction
 - Cerebrovascular disorders
 - Convulsions
 - Depression and suicide/self-injury
 - Hepatic disorders
 - Ischaemic heart disease
 - Lack of efficacy/effect
 - Peripheral neuropathy
 - Pregnancy and neonatal topics
 - Pseudomembranous colitis
 - Rhabdomyolysis/myopathy
 - Severe cutaneous adverse reactions
 - Systemic lupus erythematosus

24



SMQ Resources

- Refer to MSSO Web site for information on SMQs

http://www.meddramsso.com/subscriber_smq.asp

25



Use of SMQs at the FDA

Integrated Review - [CrossTab]


	A	B	C	D
1	SMQ name. Each SMQ carries 'SMQ' at t	CPI/r		Subjects
2	Dyslipidaemia (SMQ)	19 (4.44%)	48 (11.03%)	67 (7.74%)
3	Depression and suicide/self-injury (SMQ)	17 (3.97%)	22 (5.06%)	39 (4.50%)
4	Peripheral neuropathy (SMQ)	16 (3.74%)	19 (4.37%)	35 (4.04%)
5	Malignancies (SMQ)	11 (2.57%)	13 (2.99%)	24 (2.77%)
6	Malignant or unspecified tumours (SMQ)	11 (2.57%)	13 (2.99%)	24 (2.77%)
7	Haematopoietic cytopenias (SMQ)	12 (2.80%)	10 (2.30%)	22 (2.54%)
8	Leukopenia (SMQ)	11 (2.57%)	9 (2.07%)	20 (2.31%)
9	Asthma/bronchospasm (SMQ)	2 (0.47%)	6 (1.38%)	8 (0.92%)
10	Angioedema (SMQ)	2 (0.47%)	4 (0.92%)	6 (0.69%)
11	Acute pancreatitis (SMQ)	1 (0.23%)	4 (0.92%)	5 (0.58%)
12	Convulsions (SMQ)	3 (0.70%)	3 (0.69%)	6 (0.69%)
13	Ischaemic heart disease (SMQ)	0 (0.00%)	3 (0.69%)	3 (0.35%)
14	Acute renal failure (SMQ)	0 (0.00%)	2 (0.46%)	2 (0.23%)
15	Interstitial lung disease (SMQ)	0 (0.00%)	2 (0.46%)	2 (0.23%)
16	Embolic and thrombotic events, arterial (SMQ)	1 (0.23%)	2 (0.46%)	3 (0.35%)
17	Embolic and thrombotic events (SMQ)	3 (0.70%)	2 (0.46%)	5 (0.58%)

Acknowledgement: Dr. Chuck Cooper, Office of Translational Sciences, CDER, FDA

26



Use of SMQs at the FDA (cont)




Acknowledgement: Dr. Chuck Cooper, Office of Translational Sciences, CDER, FDA

27




Use of SMQs at the FDA (cont)



Acknowledgement: Dr. Chuck Cooper, Office of Translational Sciences, CDER, FDA

28



29

MedDRA Training Resources

Free Training	Open Registration Webinars
Coding with MedDRA	What's New in MedDRA
MedDRA Safety Data Analysis and SMQs	MedDRA Versioning
Webinar-MedDRA Coding Basics	Introduction to MedDRA
Webinar-Introduction to MedDRA Data Analysis and SMQs for Physicians	Medication Errors and Product Quality Issue Concepts in MedDRA

30



Summary

In this presentation, we:

- Demonstrated the relationship of CTCAE to MedDRA
- Briefly reviewed the structure and scope of MedDRA
- Illustrated how CTCAE 'Other, specify' verbatim reported as MedDRA could facilitate data retrieval, presentation and analysis
- Were introduced to MedDRA Standardized MedDRA Queries (SMQs)
- Presented options for MedDRA training

31



MSSO Contacts

- Mail
MedDRA MSSO
15010 Conference Center Drive
Chantilly, VA, USA 20151
- Telephone
– Toll-free Worldwide 877.258.8280 (AT&T)
- Fax (USA)
– +1 571.313.2345
- Products and Services
– Toll-free Worldwide 877.258.8280 (AT&T)

32



MSSO Contacts (cont)

- To Subscribe by
 - E-mail
 - mssohelp@mssotools.com
 - Web site
 - www.meddramsso.com select "How to Subscribe"
- Help Desk
 - Phone
 - International AT&T Toll Free: 877.258.8280
 - Direct Dial (USA): +1 571.313.2574
 - E-mail
 - mssohelp@mssotools.com